SHIP OF THESEUS, LLC
Biotech · Private
A patented HOXB4 mutant protein drug for ex vivo treatment of hematopoietic stem cells to enhance in vivo expansion before transplantation
- Grants
- $2.5M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | $293,089 | |
| Federal grant | Department of Health and Human Services · Phase II · Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant | $1,770,171 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies | $399,739 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1185 | Exxel Pharma, INC. | — | $600K |
| 1186 | Vivid Genomics, Inc. | — | — |
| 1187 | Ikena Oncology | — | $43M |
| 1188 | SHIP OF THESEUS, LLC | — | — |
| 1189 | Bridge Therapeutics, Inc. | — | $321K |
| 1190 | BioVaxys Technology Corp. | — | $301K |
| 1191 | Petri Bio LLC | — | $255K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- HOXA3 Treatment Methods For Accelerating Wound Healing In Aged Non-diabetic Miceapplication
- HOXA3 Treatment Methods For Accelerating Wound Healing In Aged Non-diabetic Miceapplication
- HOXA3 Treatment Methods For Accelerating Wound Healing Aged Non-diabetic Miceapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.